

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of claims:

1-15. (Cancelled)

16. (Currently Amended) An immunoassay kit for detecting an analyte in a test sample, comprising:

i. a first strip including a test patch that contains a predetermined amount of an antibody specifically binding to the analyte, wherein the antibody is linked to a reporter molecule capable of releasing a signal and is the only antibody in the test patch, and

ii. a second strip made of an absorbent material for absorbing the test sample the second strip being configured to be separable from the first strip, wherein ~~the first strip is configured such that~~, after contacting ~~it~~ the first strip for a fixed time period with the second strip absorbed with the test sample and then separating them, the antibody bound to the analyte moves from the first strip to the second strip and the antibody not bound to the analyte remains on the first strip, the level of signal released from the reporter molecule linked to the antibody remaining on the first strip being inversely proportional to the amount of the analyte in the test sample.

17. (Currently Amended) The immunoassay kit of claim 16, wherein the first strip further includes four reference patches containing four predetermined amounts of the reporter molecule, the levels of signal released therefrom corresponding to four determined concentrations of the ~~anlyte~~ analyte.

18. (Previously Presented) The immunoassay kit of claim 16, wherein the reporter molecule is a dye.

19. (Previously Presented) The immunoassay kit of claim 16, wherein the reporter molecule is an enzyme.

20. (Previously Presented) The immunoassay device according to claim 16, wherein the antibody binds to thromboxane B2.

21. (Cancelled)

22. (Currently Amended) The immunoassay kit according to claim 20 [[21]], wherein the first strip further includes four reference patches containing four predetermined amounts of the reporter molecule, the level of signal released therefrom corresponding to relative risks of a cardiovascular event.

23. (Previously Presented) The immunoassay kit according to claim 22, wherein the levels of signal released from the four predetermined amounts of the reporter molecule correspond to the following four amounts of urinary 11-dehydro thromboxane B2: (i) less than 15.1 ng/mmol creatinine, (ii) 15.1-21.8 ng/mmol creatinine, (iii) 21.9-33.8 ng/mmol creatinine, and (iv) higher than 33.8 ng/mmol creatinine.

24. (Previously Presented) The immunoassay kit according to claim 22, wherein the reporter molecule is a dye.

25. (Previously Presented) The immunoassay kit according to claim 22, wherein the reporter molecule is an enzyme.